Essential Premium

Big Name Hedge Funds Miss Kodiak Sciences’ 178 Percent Stock Rise

Hedge funds were unprepared to take advantage of biotech company Kodiak Sciences’ “eye-popping” clinical trial results.

Legal Forum Winter Roundtable 2027

March 3-4, 2027 | Apella

The Continuation Fund Boom Comes With Growing Regulatory Questions

A lack of exits is fueling the funds’ growth, but regulators and investors are scrutinizing valuations, disclosures, and potential conflicts of interest.

Sponsored

Why Asia and Europe Are Turning to U.S. Crude Oil

II Communities on Alternative Investments

What’s Behind the Latest Surge in Grain and Oilseed Prices?

Seligman Cuts AI Exposure, Preserving a Nearly 40 Percent Gain

Paul Wick’s tech-focused hedge fund trimmed AI winners before the summer correction, making the fund one of the year’s top performers.

Related Content

Hedge Funds Stand to Gain as Biopharma IPOs Heat Up

Steve Taub

Ken Griffin on Time Warner, ‘Flash Boys,’ the Fed and Politics

Robert Teitelman

The Flash Boys: Rebels in Search of a Cause

Michael Peltz

2027 Endowments & Foundations Roundtable West

February 8-10, 2027

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram